200 related articles for article (PubMed ID: 17428113)
1. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trial.
van Beek N; Eming R; Reuss A; Zillikens D; Sárdy M; Günther C; Kiritsi D; Benoit S; Beissert S; Gläser R; Gollnick H; Horváth ON; Pfeiffer C; Röcken M; Schauer F; Schreml S; Steinbrink K; Zink A; Schade-Brittinger C; Hertl M; Schmidt E
Br J Dermatol; 2024 Apr; 190(5):657-667. PubMed ID: 38133541
[TBL] [Abstract][Full Text] [Related]
3. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
Chen DM; Odueyungbo A; Csinady E; Gearhart L; Lehane P; Cheu M; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Musette P; Joly P;
Br J Dermatol; 2020 May; 182(5):1111-1119. PubMed ID: 31487383
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and acceptability of immunosuppressive agents for pediatric frequently-relapsing and steroid-dependent nephrotic syndrome: A network meta-analysis of randomized controlled trials.
Tan L; Li S; Yang H; Zou Q; Wan J; Li Q
Medicine (Baltimore); 2019 May; 98(22):e15927. PubMed ID: 31145359
[TBL] [Abstract][Full Text] [Related]
5. Comparison of methotrexate and azathioprine as the first-line steroid-sparing immunosuppressive agents in patients with Takayasu's arteritis.
Kaymaz-Tahra S; Bayindir O; Ince B; Ozdemir İsik O; Kutu ME; Karakas O; Yildirim TD; Ademoglu Z; Ediboglu ED; Uludogan BCE; Ilgin C; Bilge NSY; Kasifoglu T; Akar S; Emmungil H; Onen F; Omma A; Kanitez NA; Yazici A; Cefle A; Inanc M; Aksu K; Keser G; Direskeneli H; Alibaz-Oner F
Semin Arthritis Rheum; 2024 Jun; 66():152446. PubMed ID: 38669786
[TBL] [Abstract][Full Text] [Related]
6. Azathioprine vs methotrexate in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective study.
Milanesi A; Delvino P; Quaglini S; Montecucco C; Monti S
Rheumatology (Oxford); 2024 Apr; 63(4):945-952. PubMed ID: 37326880
[TBL] [Abstract][Full Text] [Related]
7. Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.
Tedbirt B; Maho-Vaillant M; Houivet E; Mignard C; Golinski ML; Calbo S; Prost-Squarcioni C; Labeille B; Picard-Dahan C; Chaby G; Richard MA; Tancrede-Bohin E; Duvert-Lehembre S; Delaporte E; Bernard P; Caux F; Alexandre M; Musette P; Ingen-Housz-Oro S; Vabres P; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bédane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Joly P; Hébert V;
JAMA Dermatol; 2024 Mar; 160(3):290-296. PubMed ID: 38265821
[TBL] [Abstract][Full Text] [Related]
8. [Pemphigus: current and future treatment strategies].
Kussini J; Kaisers T; Sequeira Santos AM; Eming R; Didona D
Dermatologie (Heidelb); 2022 Dec; 74(12):915-926. PubMed ID: 37902884
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of clinical factors and outcome of systemic glucocorticoid therapy discontinuation in patients with pemphigus achieving complete remission.
Wang M; Li J; Shang P; Chong S; Chen Y; Zhao L; Wang R; Fan B; Li F; Chen X; Zhang Y; Zhao J; Dang J; Chen X; Zhu X
J Dermatol; 2023 Oct; 50(10):1347-1352. PubMed ID: 37248863
[TBL] [Abstract][Full Text] [Related]
10. Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases.
Malpica L; Moll S
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):319-327. PubMed ID: 33275674
[TBL] [Abstract][Full Text] [Related]
11. Maintenance treatment of pemphigus with rituximab in real life: A single-center study of 50 patients.
Louchez A; El Aarbaoui T; Weill A; Gaudin O; Jelti L; Belmondo T; Wolkenstein P; Ingen-Housz-Oro S
Ann Dermatol Venereol; 2024 Jun; 151(2):103264. PubMed ID: 38537431
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone-cyclophosphamide pulse therapy outcomes comparing pemphigus vulgaris and pemphigus foliaceus groups in a Brazilian cohort study.
Fontenelle LF; Bueno-Filho R; Vernal S; Delfino R; Barbosa GSL; Donadi EA; Roselino AM
An Bras Dermatol; 2023; 98(6):774-780. PubMed ID: 37355353
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids.
Yunyun F; Yu C; Panpan Z; Hua C; Di W; Lidan Z; Linyi P; Li W; Qingjun W; Xuan Z; Yan Z; Xiaofeng Z; Fengchun Z; Wen Z
Sci Rep; 2017 Jul; 7(1):6195. PubMed ID: 28733656
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling.
Deakin CT; Campanilho-Marques R; Simou S; Moraitis E; Wedderburn LR; Pullenayegum E; Pilkington CA;
Arthritis Rheumatol; 2018 May; 70(5):785-793. PubMed ID: 29342499
[TBL] [Abstract][Full Text] [Related]
15. Success with single-agent immunosuppression for multifocal choroidopathies.
Goldberg NR; Lyu T; Moshier E; Godbold J; Jabs DA
Am J Ophthalmol; 2014 Dec; 158(6):1310-7. PubMed ID: 25194229
[TBL] [Abstract][Full Text] [Related]
16. Pemphigus Vegetans of Hallopeau: A Case Report.
Maljić J; Radoš J; Lončarić D; Lakoš Jukić I
Acta Dermatovenerol Croat; 2023 Aug; 31(1):43-44. PubMed ID: 37843091
[TBL] [Abstract][Full Text] [Related]
17. Deep pemphigus (pemphigus vulgaris, pemphigus vegetans and paraneoplastic pemphigus) in dogs, cats and horses: a comprehensive review.
Tham HL; Linder KE; Olivry T
BMC Vet Res; 2020 Nov; 16(1):457. PubMed ID: 33228633
[TBL] [Abstract][Full Text] [Related]
18. Comparison of tacrolimus with or without prednisone therapy in primary membranous nephropathy: a retrospective clinical study.
Zhang X; Dou J; Gao G; Sheng X; Shen Y; Feng Y; Wu X; Zhang Z; Cheng G
Sci Rep; 2024 Jun; 14(1):14214. PubMed ID: 38902302
[TBL] [Abstract][Full Text] [Related]
19. The use of oclacitinib compared to azathioprine in the management of canine pemphigus foliaceus: A retrospective analysis.
Hernandez-Bures A; Bidot WA; Griffin CE; Rosenkrantz WS
Vet Dermatol; 2023 Dec; 34(6):554-566. PubMed ID: 37700599
[TBL] [Abstract][Full Text] [Related]
20. Treatment with immunosuppressants did not increase the risk of COVID-19 in pemphigus patients: A single-center survey-based study.
Feng X; Zhou X; Zhang X; Xiao Y; Li F; Mi W; Gao J; Wang J; Zhou Y; Wang M; Wang W; Li W
Int Immunopharmacol; 2024 Jun; 135():112307. PubMed ID: 38796966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
